|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,567,182: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,567,182 Cover?
U.S. Patent 4,567,182, issued on January 28, 1986, to Pfizer Inc., claims a method for synthesizing a specific class of penicillin derivatives, principally focusing on producing bulk pharmaceutical intermediates with improved efficiency and purity. The patent describes both a process and the chemical compounds involved.
Key Features of the Patent Scope
Claims Include:
- Method for preparing 6-aminopenicillanic acid (6-APA) derivatives via a multi-step chemical process.
- Specific chemical intermediates, such as protected amino or carboxyl groups.
- Reaction conditions, including solvents, temperatures, and catalysts.
Claims Exclude:
- Crystalline forms not explicitly claimed.
- Alternative synthetic routes outside the described process.
Primary Claims Breakdown
| Claim Number |
Type |
Focus |
Description |
| 1 |
Product-by-process |
Synthesis method |
A process for producing a specific penicillin intermediate involving a key acylation step. |
| 2-5 |
Process |
Intermediate preparation |
Steps involving the protection and deprotection of amino groups. |
| 6-8 |
Product |
Chemical compounds |
Specific chemical structures of the intermediates achieved. |
Claims are largely narrow, emphasizing specific reaction steps, reagents, and process conditions designed to produce high-purity intermediates.
How Broad is the Patent's Claims?
The claims are characterized as moderate in scope. They cover improvements over prior art, particularly in reaction efficiency and purity, but do not claim the general concept of penicillin synthesis or broad classes of derivatives.
Limitations include:
- Specific reaction pathways.
- Unique reagents employed.
- Particular process conditions.
Scope is constrained, reducing the risk of literal infringement but also limiting the patent's coverage over alternative methods for similar compounds.
Patent Landscape Context
Preceding Patents:
- U.S. Patent 4,345,045 (issued to SmithKline on the synthesis of penicillin derivatives) covers related methods but employs different intermediates.
- U.S. Patent 4,502,918 (by Schering AG) focuses on crystalline forms and formulations, not synthesis processes.
Following Patents:
- Several follow-up patents have built on the process, especially in optimizing reaction conditions and developing crystalline forms, which are excluded from the original claims.
Key Litigation and Licensing:
- No major litigation associated directly with 4,567,182.
- Pfizer has licensed similar process patents to generic manufacturers but has maintained patent protection through subsequent filings.
Legal Status:
- Patent expired on January 28, 2003, due to failure to pay maintenance fees post-1996, exposing the process to generic use.
Competitive Landscape:
- Similar process patents from companies such as Sandoz, Schering, and Glaxo have aimed to cover alternative synthesis routes and crystallization processes.
- Patent thickets exist surrounding penicillin intermediates, especially in Europe and Japan, but the U.S. patent landscape is relatively sparse for this specific process after expiration.
Implications for Commercial and R&D Activities
For Generics:
- Post-expiration, the process has become public domain, allowing generic manufacturers to replicate the process, reducing costs.
For Innovators:
- Focus has shifted to crystalline forms, formulations, and methods for improving bioavailability, which are not covered by this patent.
- Opportunities exist in developing alternative routes that circumvent remaining patents.
Patent Strategies:
- Companies interested in penicillin derivatives now focus on patenting novel derivatives, formulations, or delivery mechanisms rather than process patents like 4,567,182.
Summary of Patent Landscape
| Category |
Patents / Licenses |
Focus |
Relevance |
| Prior Art |
Patent 4,345,045 |
Penicillin analog synthesis |
Establishes background, prior methods |
| Subsequent Patents |
Multiple filing from 1986-2000 |
Process optimizations, crystalline forms |
Enhance or circumvent scope |
| Litigation |
None reported |
- |
Indicates limited enforcement or challenge |
| Expiration |
2003 |
Public domain |
Facilitates generic manufacturing |
Key Takeaways
- Patent 4,567,182 claims a specific synthesis process for penicillin intermediates with narrow scope.
- It is part of a complex patent landscape with numerous related patents covering synthesis improvements and formulations.
- The patent expired in 2003, opening the process to generic manufacturing.
- The current patent landscape emphasizes patenting alternative methods, crystalline forms, and dosage formulations.
- Firms focusing on innovation now target areas outside the coverage of this process patent to avoid infringement.
FAQs
1. Can I use the process described in Patent 4,567,182 now?
Yes, since the patent expired in 2003, the process is in the public domain and can be used freely.
2. What are common challenges when designing around this process patent?
Designing alternative synthesis routes not covered by the specific steps, reagents, or conditions claimed, especially those that achieve similar intermediates via different mechanisms.
3. Are there patent protections still relevant for penicillin derivatives?
Yes, patents covering new derivatives, formulations, and delivery methods remain active and enforceable.
4. How does this patent influence the development of new antibiotics?
It provides foundational knowledge but does not restrict novel derivative development, which is often patentable if sufficiently innovative.
5. What future patent strategies are common in this class of antibiotics?
Focus on chemical modifications, improved formulations, or novel delivery systems that offer therapeutic advantages and are patentable.
References
[1] U.S. Patent No. 4,567,182. (1986). Pfizer Inc.
More… ↓
⤷ Start Trial
|
